Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,otherCurrentAssets,longTermInvestments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,investments,repurchaseOfStock,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,currency,priceHint,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 14, 2019) 4","Short Ratio (Aug 14, 2019) 4","Short % of Float (Aug 14, 2019) 4","Short % of Shares Outstanding (Aug 14, 2019) 4","Shares Short (prior month Jun 27, 2019) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,EMMA,-17569000.0,48987200,725000,,-26058000,-725000,-26137000,6880000,5906000,-1699000,-1699000,,-7318000,,,,25000,6084000,7783000,178000,-24359000,,-26083000,-26137000,44000.0,199395000.0,74732000.0,-17525000.0,5676000.0,56482000.0,47000.0,-216916000.0,34585000.0,-51000.0,383000.0,13546000.0,35233000.0,13928000.0,-51000.0,4281000.0,51774000.0,27643000.0,1900000.0,1200000.0,7491000.0,794000.0,,,0.0,,,,,,,,,,,,,,,,,16541000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,1.55 - 1.55,1.55,0.0,0.0,18,13,finmb_39585025,Other OTC,"Emmaus Life Sciences, Inc.",USD,5164,6950,0.84999996,1.2142857,0.7 - 1.89,-0.34000003,-0.1798942,0.7,1.89,1563408000,1573583400,1573583400,1573583400,-2.089,-4.62,USD,4,-0.368,1.4909723,0.05902767,0.039590053,1.4912174,0.058782578,0.03941919,75930160,-0.33549783,-4.2119565,15,America/New_York,EDT,-14400000,PNK,0,False,False,1.55,1630425853,0.0,1.5,1.55,1.55,652,EMMAUS LIFE SCIENCES INC NEW,us_market,REGULAR,,,,1.89,0.7,1.491,1.4912,5.16k,6.95k,48.99M,,33.96M,40.64%,0.00%,41.22k,0.48,0.09%,0.09%,33.64k,,,,,,0.00%,"Jul 17, 2019",,1:6,"Jul 17, 2019","Dec 30, 2019","Sep 29, 2019",-241.04%,-9.28%,-1.96%,,22.75M,0.54,24.60%,21.66M,-2.04M,-54.84M,-2.0890,,41.19M,0.84,23.77M,,1.26,-0.37,-4.52M,-395.62k,Value,90503,Healthcare,"Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Emmaus Life Sciences, Inc. has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. is headquartered in Torrance, California.",Torrance,310 214 0065,CA,1577750400,United States,http://www.emmausmedical.com,86400,21250 Hawthorne Boulevard,310 214 0075,Biotechnology,Suite 800
t-1,EMMA,-36439000.0,48987200,725000,,-18633000,-785000,-18633000,6294000,5674000,-620000,-620000,,-7318000,,,,0,5869000,6489000,195000,-18013000,,-18633000,-18633000,,,98715000.0,-36439000.0,6116000.0,61491000.0,-36439000.0,,40311000.0,,4697000.0,15169000.0,57251000.0,28047000.0,,145000.0,56649000.0,32890000.0,1981000.0,1153000.0,5906000.0,11455000.0,,,0.0,,,,,,,,,,,,,,,,,-602000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,1.55 - 1.55,1.55,0.0,0.0,18,13,finmb_39585025,Other OTC,"Emmaus Life Sciences, Inc.",USD,5164,6950,0.84999996,1.2142857,0.7 - 1.89,-0.34000003,-0.1798942,0.7,1.89,1563408000,1573583400,1573583400,1573583400,-2.089,-4.62,USD,4,-0.368,1.4909723,0.05902767,0.039590053,1.4912174,0.058782578,0.03941919,75930160,-0.33549783,-4.2119565,15,America/New_York,EDT,-14400000,PNK,0,False,False,1.55,1630425853,0.0,1.5,1.55,1.55,652,EMMAUS LIFE SCIENCES INC NEW,us_market,REGULAR,,,,1.89,0.7,1.491,1.4912,5.16k,6.95k,48.99M,,33.96M,40.64%,0.00%,41.22k,0.48,0.09%,0.09%,33.64k,,,,,,0.00%,"Jul 17, 2019",,1:6,"Jul 17, 2019","Dec 30, 2019","Sep 29, 2019",-241.04%,-9.28%,-1.96%,,22.75M,0.54,24.60%,21.66M,-2.04M,-54.84M,-2.0890,,41.19M,0.84,23.77M,,1.26,-0.37,-4.52M,-395.62k,Value,90503,Healthcare,"Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Emmaus Life Sciences, Inc. has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. is headquartered in Torrance, California.",Torrance,310 214 0065,CA,1577750400,United States,http://www.emmausmedical.com,86400,21250 Hawthorne Boulevard,310 214 0075,Biotechnology,Suite 800
t-2,EMMA,-24596000.0,48987200,513000,,-14153000,-82000,-14167000,5166000,5107000,-572000,-572000,,-6965000,,,,0,5307000,5879000,200000,-13581000,,-14153000,-14167000,50000.0,146344000.0,95363000.0,-24546000.0,5217000.0,70735000.0,36000.0,-170864000.0,37084000.0,-62000.0,360000.0,15310000.0,53490000.0,15157000.0,-62000.0,2991000.0,66807000.0,42873000.0,1760000.0,2311000.0,5795000.0,692000.0,251000.0,527000.0,2839000.0,-16000.0,-3048000.0,-492000.0,-1150000.0,2556000.0,-1770000.0,22000.0,-1284000.0,17000.0,-1091000.0,-409000.0,7036000.0,-16000.0,,,,13317000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,1.55 - 1.55,1.55,0.0,0.0,18,13,finmb_39585025,Other OTC,"Emmaus Life Sciences, Inc.",USD,5164,6950,0.84999996,1.2142857,0.7 - 1.89,-0.34000003,-0.1798942,0.7,1.89,1563408000,1573583400,1573583400,1573583400,-2.089,-4.62,USD,4,-0.368,1.4909723,0.05902767,0.039590053,1.4912174,0.058782578,0.03941919,75930160,-0.33549783,-4.2119565,15,America/New_York,EDT,-14400000,PNK,0,False,False,1.55,1630425853,0.0,1.5,1.55,1.55,652,EMMAUS LIFE SCIENCES INC NEW,us_market,REGULAR,,,,1.89,0.7,1.491,1.4912,5.16k,6.95k,48.99M,,33.96M,40.64%,0.00%,41.22k,0.48,0.09%,0.09%,33.64k,,,,,,0.00%,"Jul 17, 2019",,1:6,"Jul 17, 2019","Dec 30, 2019","Sep 29, 2019",-241.04%,-9.28%,-1.96%,,22.75M,0.54,24.60%,21.66M,-2.04M,-54.84M,-2.0890,,41.19M,0.84,23.77M,,1.26,-0.37,-4.52M,-395.62k,Value,90503,Healthcare,"Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Emmaus Life Sciences, Inc. has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. is headquartered in Torrance, California.",Torrance,310 214 0065,CA,1577750400,United States,http://www.emmausmedical.com,86400,21250 Hawthorne Boulevard,310 214 0075,Biotechnology,Suite 800
t-3,EMMA,-15850949.0,48987200,449610,,-19165769,-97094,-19023892,6896595,6575225,-770980,-770980,,-6556657,,,,3822,6842165,7613145,266940,-18394789,,-19169591,-19023892,53760.0,140903946.0,90449470.0,-15797189.0,5199458.0,74555187.0,35559.0,-156667567.0,37888194.0,-69127.0,352103.0,17079734.0,37526790.0,11253348.0,-69127.0,151686.0,73459436.0,49342776.0,1361043.0,15034486.0,4704571.0,937190.0,238304.0,538202.0,2045296.0,19544.0,4012833.0,1304778.0,-674131.0,1005650.0,417523.0,9083.0,-915882.0,17011.0,-1351978.0,66218.0,12808895.0,-12653.0,32197.0,-3762000.0,48295.0,35932646.0,en-US,US,EQUITY,False,Delayed Quote,0.0,1.55 - 1.55,1.55,0.0,0.0,18,13,finmb_39585025,Other OTC,"Emmaus Life Sciences, Inc.",USD,5164,6950,0.84999996,1.2142857,0.7 - 1.89,-0.34000003,-0.1798942,0.7,1.89,1563408000,1573583400,1573583400,1573583400,-2.089,-4.62,USD,4,-0.368,1.4909723,0.05902767,0.039590053,1.4912174,0.058782578,0.03941919,75930160,-0.33549783,-4.2119565,15,America/New_York,EDT,-14400000,PNK,0,False,False,1.55,1630425853,0.0,1.5,1.55,1.55,652,EMMAUS LIFE SCIENCES INC NEW,us_market,REGULAR,,,,1.89,0.7,1.491,1.4912,5.16k,6.95k,48.99M,,33.96M,40.64%,0.00%,41.22k,0.48,0.09%,0.09%,33.64k,,,,,,0.00%,"Jul 17, 2019",,1:6,"Jul 17, 2019","Dec 30, 2019","Sep 29, 2019",-241.04%,-9.28%,-1.96%,,22.75M,0.54,24.60%,21.66M,-2.04M,-54.84M,-2.0890,,41.19M,0.84,23.77M,,1.26,-0.37,-4.52M,-395.62k,Value,90503,Healthcare,"Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Emmaus Life Sciences, Inc. has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. is headquartered in Torrance, California.",Torrance,310 214 0065,CA,1577750400,United States,http://www.emmausmedical.com,86400,21250 Hawthorne Boulevard,310 214 0075,Biotechnology,Suite 800
